Adamed backs €15M raise in One Biosciences to pioneer AI-driven oncology
Category: MedTech / Biotech / Investment Tags: MedTech, Biotech, Poland
Polish pharma leader Adamed joins €15M Series A for One Biosciences to accelerate AI-powered precision oncology breakthroughs
In a major win for Poland’s growing presence in the global healthtech scene, Adamed, one of the country’s leading pharmaceutical and biotechnology companies, has joined an elite group of investors backing One Biosciences, a French biotech startup revolutionizing cancer diagnostics and treatment.
The Paris-based One Biosciences has raised €15 million in Series A funding to scale its clinical-grade single-cell tumor profiling platform, designed to optimize treatment selection in oncology through AI-powered analysis of tumor heterogeneity. With this round, the company’s total funding climbs to €20 million.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
The funding will help One Biosciences fast-track the development of its proprietary platform, validate its technology in clinical trials, and prepare market entry into the US and other international health systems.
A Polish Pillar in a Global MedTech Deal
The presence of Adamed in this international syndicate sends a strong signal: Poland is no longer just a consumer of global medical innovation — it is becoming a co-creator.
With over 40 years of legacy and a robust R&D hub in Pabianice, Adamed has been steadily expanding into precision medicine, digital health, and advanced diagnostics through its venture arm, Adamed Technology. The investment in One Biosciences aligns with Adamed’s strategy to build partnerships with cutting-edge biotech companies that can transform the future of personalized therapies and patient-centric diagnostics.
“This investment offers not only capital, but strategic synergy,” said a spokesperson for Adamed. “We see the future of oncology as multi-disciplinary and data-driven. One Biosciences’ technology could change how clinicians make decisions, and we’re proud to support that mission from the heart of Europe.”
From France to the World – with a Polish Boost
Founded at the Institut Curie, One Biosciences is a pioneer in decoding tumor heterogeneity using single-cell RNA sequencing and machine learning. By examining how individual cancer cells respond to different therapies, the company’s AI models can predict which treatments are most likely to work — making it possible to tailor therapies to each patient with greater precision.
“At the core of our mission is the belief that understanding tumor diversity at the cellular level will redefine oncology,” said Hedi Ben Brahim, CEO of One Biosciences. “This funding allows us to translate our breakthrough single-cell platform into clinical practice faster — with Adamed as a key ally in Central and Eastern Europe.”
Dr. Céline Vallot, co-founder and scientific lead, emphasized the AI angle: “We’re continuously refining our models by training them on proprietary datasets derived from actual patient tumors. This allows us to develop predictive biomarkers for drug response, potentially optimizing the entire pharmaceutical development pipeline.”
Adamed’s Strategic Shift Toward Digital and AI-Driven Health
Adamed’s role in the deal is not just financial. The company has been actively repositioning itself as a European leader in medtech and digital therapeutics, supporting ventures in diagnostics, AI, and drug personalization. Through its Adamed SmartUP program, it is nurturing the next generation of healthtech founders and data scientists. This co-investment in One Biosciences also opens doors for clinical collaboration, knowledge sharing, and potential pilots or trials across Polish hospitals and research centers.
Poland’s health system, which is rapidly adopting AI in imaging and diagnostics, stands to benefit from such advanced tumor profiling technologies — particularly in addressing the rising burden of oncological diseases, now the second leading cause of death in the country.
European AI + Oncology = A New Frontier
One Biosciences joins a wave of next-gen biotech startups harnessing artificial intelligence to redefine cancer treatment. This shift reflects a broader trend in European health innovation: merging biology, data science, and patient care. As more VCs, corporates, and institutions back precision oncology platforms, the presence of CEE-based investors like Adamed signals a tectonic shift — one where Poland is not just catching up, but actively shaping the future of global medicine.
